Optimizing medication appropriateness in older adults: a randomized clinical interventional trial to decrease anticholinergic burden

Daniela C Moga, Erin L Abner, Dorinda N Rigsby, Lynne Eckmann, Mark Huffmyer, Richard R Murphy, Beth B Coy, Gregory A Jicha, Daniela C Moga, Erin L Abner, Dorinda N Rigsby, Lynne Eckmann, Mark Huffmyer, Richard R Murphy, Beth B Coy, Gregory A Jicha

Abstract

Background: The complexity of medication therapy in older adults with multiple comorbidities often leads to inappropriate prescribing. Drugs with anticholinergic properties are of particular interest because many are not recognized for this property; their use may lead to increased anticholinergic burden resulting in significant health risks, as well as negatively impacting cognition. Medication therapy management (MTM) interventions showed promise in addressing inappropriate medication use, but the effectiveness of targeted multidisciplinary team interventions addressing anticholinergic medications in older populations is yet to be determined.

Methods: We conducted an 8-week, parallel-arm, randomized trial to evaluate whether a targeted patient-centered pharmacist-physician team MTM intervention ("targeted MTM intervention") reduced the use of inappropriate anticholinergic medications in older patients enrolled in a longitudinal cohort at University of Kentucky's Alzheimer's Disease Center. Study outcomes included changes in the medication appropriateness index (MAI) targeting anticholinergic medications and in the anticholinergic drug scale (ADS) score from baseline to the end of study.

Results: Between October 1, 2014 and September 30, 2015 we enrolled and randomized 50 participants taking at least one medication with anticholinergic properties. Of these, 35 (70%) were women, 45 (90%) were white, and 33 (66%) were cognitively intact (clinical dementia rating [CDR] = 0); mean age was 77.7 ± 6.6 years. At baseline, the mean MAI was 12.6 ± 6.3; 25 (50%) of the participants used two or more anticholinergics, and the mean ADS score was 2.8 ± 1.6. After randomization, although no statistically significant difference was noted between groups, we identified a potentially meaningful imbalance as the intervention group had more participants with intact cognition, and thus included CDR in all of the analyses. The targeted MTM intervention resulted in statistically significant CDR adjusted differences between groups with regard to improved MAI (change score of 3.6 (1.1) for the MTM group as compared with 1.0 (0.9) for the control group, p = 0.04) and ADS (change score of 1.0 (0.3) for the MTM group as compared with 0.2 (0.3) for the control group, p = 0.03).

Conclusions: Our targeted MTM intervention resulted in improvement in anticholinergic medication appropriateness and reduced the use of inappropriate anticholinergic medications in older patients. Our results show promise in an area of great importance to ensure optimum outcomes for medications used in older adults.

Trial registration: ClinicalTrials.gov NCT02172612 . Registered 20 June 2014.

Keywords: Alzheimer’s Disease Center; Anticholinergic medication; Medication therapy management intervention; Older adults.

Figures

Fig. 1
Fig. 1
Study procedures. ADC Alzheimer’s Disease Center
Fig. 2
Fig. 2
Flow diagram: study participation and selection process

References

    1. Lau DT, et al. Polypharmacy and potentially inappropriate medication use among community-dwelling elders with dementia. Alzheimer Dis Assoc Disord. 2010;24(1):56–63. doi: 10.1097/WAD.0b013e31819d6ec9.
    1. Fick DM, et al. Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts. Arch Intern Med. 2003;163(22):2716–24. doi: 10.1001/archinte.163.22.2716.
    1. Gu Q, Dillon CF, Burt VL. Prescription drug use continues to increase: U.S. prescription drug data for 2007-2008 NCHS data brief. NCHS Data Brief. 2010;(42):1–8.
    1. Farrell B, Szeto W, Shamji S. Drug-related problems in the frail elderly. Can Fam Physician. 2011;57(2):168–9.
    1. Cummings JL, Back C. The cholinergic hypothesis of neuropsychiatric symptoms in Alzheimer’s disease. Am J Geriatr Psychiatry. 1998;6(2 Suppl 1):S64–78. doi: 10.1097/00019442-199821001-00009.
    1. Lemstra AW, Eikelenboom P, van Gool WA. The cholinergic deficiency syndrome and its therapeutic implications. Gerontology. 2003;49(1):55–60. doi: 10.1159/000066508.
    1. Sunderland T, et al. Anticholinergic sensitivity in patients with dementia of the Alzheimer type and age-matched controls. A dose-response study. Arch Gen Psychiatry. 1987;44(5):418–26. doi: 10.1001/archpsyc.1987.01800170032006.
    1. Kay G, et al. Antimuscarinic drugs for overactive bladder and their potential effects on cognitive function in older patients. J Am Geriat Soc. 2005;53(12):2195–201.
    1. Jewart RD, et al. Cognitive, behavioral, and physiological changes in Alzheimer disease patients as a function of incontinence medications. Am J Geriatr Psychiatry. 2005;13(4):324–8. doi: 10.1097/00019442-200504000-00009.
    1. Siegel S. An introduction to the Medicare Prescription Drug, Improvement, and Modernization Act of 2003. Health Care Law Mon. 2004:3–14.
    1. Patterson SM, et al. Interventions to improve the appropriate use of polypharmacy for older people. Cochrane Database Syst Rev. 2012;5:CD008165.
    1. Brown W, Maack B, Mehling M. Medication therapy management: teaming with pharmacists for improved patient care. JAAPA. 2013;26(12):40–3.
    1. Kersten H, et al. Cognitive effects of reducing anticholinergic drug burden in a frail elderly population: a randomized controlled trial. J Gerontol A Biol Sci Med Sci. 2013;68(3):271–8. doi: 10.1093/gerona/gls176.
    1. Steinman MA. Polypharmacy and the balance of medication benefits and risks. Am J Geriatr Pharmacother. 2007;5(4):314–6. doi: 10.1016/j.amjopharm.2007.12.009.
    1. American Geriatrics Society 2012 Beers Criteria Update Expert Panel. American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2012;60(4):616–31.
    1. Carnahan R, et al. The Anticholinergic Drug Scale as a measure of drug-related anticholinergic burden: associations with serum anticholinergic activity. J Clin Pharmacol. 2006;46:1481–6. doi: 10.1177/0091270006292126.
    1. Chew ML, Mulsant BH, Pollock BG. Serum anticholinergic activity and cognition in patients with moderate-to-severe dementia. Am J Geriatr Psychiatry. 2005;13(6):535–8. doi: 10.1097/00019442-200506000-00013.
    1. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43(11):2412–4. doi: 10.1212/WNL.43.11.2412-a.
    1. Gray SL, et al. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. JAMA Intern Med. 2015;175(3):401–7. doi: 10.1001/jamainternmed.2014.7663.
    1. Hanlon JT, et al. A method for assessing drug therapy appropriateness. J Clin Epidemiol. 1992;45(10):1045–51. doi: 10.1016/0895-4356(92)90144-C.
    1. Salahudeen MS, Duffull SB, Nishtala PS. Anticholinergic burden quantified by anticholinergic risk scales and adverse outcomes in older people: a systematic review. BMC Geriatr. 2015;15:31. doi: 10.1186/s12877-015-0029-9.
    1. Stewart AL, Ware JE, Jr, Brook RH. Advances in the measurement of functional status: construction of aggregate indexes. Med Care. 1981;19(5):473–88. doi: 10.1097/00005650-198105000-00001.
    1. Bartsch LJ, et al. Examining the SF-36 in an older population: analysis of data and presentation of Australian adult reference scores from the Dynamic Analyses to Optimise Ageing (DYNOPTA) project. Qual Life Res. 2011;20(8):1227–36. doi: 10.1007/s11136-011-9864-0.
    1. Gilson BS, et al. The sickness impact profile. Development of an outcome measure of health care. Am J Public Health. 1975;65(12):1304–10. doi: 10.2105/AJPH.65.12.1304.
    1. Weinberger M, et al. An evaluation of a brief health status measure in elderly veterans. J Am Geriatr Soc. 1991;39(7):691–4. doi: 10.1111/j.1532-5415.1991.tb03623.x.
    1. Hanlon JT, Schmader KE. The medication appropriateness index at 20: where it started, where it has been, and where it may be going. Drugs Aging. 2013;30(11):893–900. doi: 10.1007/s40266-013-0118-4.
    1. Hanlon JT, et al. A randomized, controlled trial of a clinical pharmacist intervention to improve inappropriate prescribing in elderly outpatients with polypharmacy. Am J Med. 1996;100(4):428–37. doi: 10.1016/S0002-9343(97)89519-8.
    1. McDonough RP, et al. An evaluation of managing and educating patients on the risk of glucocorticoid-induced osteoporosis. Value Health. 2005;8(1):24–31. doi: 10.1111/j.1524-4733.2005.04007.x.
    1. Gattis WA, et al. Reduction in heart failure events by the addition of a clinical pharmacist to the heart failure management team: results of the Pharmacist in Heart Failure Assessment Recommendation and Monitoring (PHARM) Study. Arch Intern Med. 1999;159(16):1939–45. doi: 10.1001/archinte.159.16.1939.
    1. Pitkala KH, et al. Education to reduce potentially harmful medication use among residents of assisted living facilities: a randomized controlled trial. J Am Med Dir Assoc. 2014;15(12):892–8. doi: 10.1016/j.jamda.2014.04.002.
    1. Sellors J, et al. A randomized controlled trial of a pharmacist consultation program for family physicians and their elderly patients. CMAJ. 2003;169(1):17–22.
    1. Taylor CT, Byrd DC, Krueger K. Improving primary care in rural Alabama with a pharmacy initiative. Am J Health Syst Pharm. 2003;60(11):1123–9.
    1. Krska J, et al. Pharmacist-led medication review in patients over 65: a randomized, controlled trial in primary care. Age Ageing. 2001;30(3):205–11. doi: 10.1093/ageing/30.3.205.
    1. Viswanathan M, Kahwati LC, Golin CE, et al. Medication Therapy Management Interventions in Outpatient Settings [Internet]. Rockville: Agency for Healthcare Research and Quality (US); 2014. (Comparative Effectiveness Reviews, No. 138). Available from: .
    1. Duran CE, Azermai M, Vander Stichele RH. Systematic review of anticholinergic risk scales in older adults. Eur J Clin Pharmacol. 2013;69(7):1485–96. doi: 10.1007/s00228-013-1499-3.
    1. Naples JG, et al. Concordance between anticholinergic burden scales. J Am Geriatr Soc. 2015;63(10):2120–4. doi: 10.1111/jgs.13647.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する